JN MEDICAL CORP

JN-International Medical Corporation is a U. S. based biopharmaceutical corporation which since 1998 has been focused on developing vaccines and diagnostics for infectious disease for developing countries. JN-International Medical Corporation (JNI) has overseas business offices and clinical trial centers located in Abidjan, Ivory Coast in Africa and in Kuala Lumpur, Malaysia, with vaccine cold chain facilities in Burkina Faso and Singapore. JNI partners with Global Health Organizations such as the Clinton Global Initiative, the Global Business Coalition, New York[2], President's Malaria Initiative and PEPFAR. JNI also partners with several other non-profit global health organizations, NGOs, local governments and communities in developing countries to address the health issues related to HIV AIDS Malaria Tuberculosis and Bacterial Meningitis that scourges the underserved communities in West Africa, South East Asia and Latin America.
An Inc 5000 company, making it the 95th ranking company in the United States and the 3rd biopharmaceutical global corporation produces Meningitis vaccines for which it holds the international intellectual property rights (IPR) . JN boats a decade of Achievements:
The world's first serological rapid tests for Tuberculosis. 2001
Prevention of mother-to-child transmission of HIV in South East Asia. 1999-2003
Prevention of Malaria in Zambia. 2007
Inexpensive vaccine for Meningitis A, C, Y & W-135 disease. 2007
Development of preventive and therapeutic vaccine for Stroke 2001-2008

Related Suppliers By Main Products